[Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation]

Recent clinical evidence that anti-PD-1/PD-L1 antibody therapy is superior to cytotoxic chemotherapy for patients with non-small cell lung cancer(NSCLC)that expresses PD-L1 has lead to a paradigm shift in treatment strategies for those patients. However, efficacy of anti-PD-1/PD-L1 antibodies for patients with NSCLC harboring EGFR mutation is generally poor. This lack ofresponse is at least partially attributed to suppression oftumor infiltrating lymphocytes caused by EGFR pathway activation or to low non-synonymous mutation load in NSCLC with EGFR mutation. However, anti-PD-1/PD-L1 antibodies may play some roles in patients who acquired resistance against EGFR tyrosine kinase inhibitors. In this review, relationship between patients with EGFR mutation and treatment using immune-checkpoint inhibitors is summarized.